

# Caladrius Biosciences

**Pharma & biotech**
**8 May 2018**

## Cell therapy platforms for unmet need

Caladrius is developing cell therapy (CT) products that extract, expand and bolster a patient's own (autologous) immune cells to treat diseases. CLBS03 is a potentially transformative Phase II candidate for recent-onset type I diabetes (T1D), and CLBS14 and CLBS12 target ischemic injury conditions.

### CLBS03 immune modulation for T1D

CLBS03 seeks to reduce or halt disease progression by preserving the patient's insulin-producing beta pancreas cells (BPC). Immune T regulatory cells (Tregs) normally modulate the activity of effector T-cells, helping to ensure that host cells are not attacked. In autoimmune diseases like T1D, deficient Treg activity may permit effector T-cells to attack the body's own cells (eg BPC in T1D). CLBS03 modifies the patient's Tregs before reintroduction, aiming to restore immune tolerance to BPC. If effective, this can reduce the need for lifelong insulin therapy.

### Recruitment completed in CLBS03 Phase II T1D study

Two Phase I trials of autologous expanded Tregs demonstrated safety and effect durability (a single dose was detectable at 12 months). In one of the studies, c 66% of children treated (n=12) were in remission at 12 months vs only 20% of control (n=10). A double-blinded 110-pt Phase II trial evaluating CLBS03 in adolescents with recent onset T1D began in Q116 and completed enrolment in Q118. An interim analysis on c 50% of patients at six months of follow-up was deemed non-futile for therapeutic effect. The 12-month top-line data are expected in Q119.

### CD34 platform targeting ischemia indications

Caladrius's CD34+ cell therapy candidates (CLBS14 and CLBS12) are intended to promote the new blood vessel formation in conditions resulting from ischemia (lack of oxygenated blood flow). A 35-pt Phase II open-label CLBS12 study started in Q118 in Japan (data expected in H219) for critical limb ischemia, a painful condition that often leads to amputation. The trial can be sufficient for a conditional approval in Japan if preliminary effectiveness is shown. A US grant-funded Phase I/II CLBS14 study in coronary microvascular dysfunction is planned to start in Q218.

### Valuation: Negative EV given \$55m net cash

Caladrius had \$55.1m net cash at YE17 (excluding \$5m in restricted cash). Assuming its forward operating cash burn rate is consistent with its 2017 rate of \$20.9m, the company should have sufficient funds to generate top-line data CLBS03 and CLBS12 programs, key potential value drivers.

Consensus estimates							
Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)	
12/16	0.0	(31.3)	(4.74)	0.00	N/A	N/A	
12/17	0.0	(27.7)	(1.78)	0.00	N/A	N/A	
12/18e	0.0	(26.3)	(3.05)	0.00	N/A	N/A	
12/19e	0.0	(30.6)	(2.32)	0.00	N/A	N/A	

Source: Bloomberg

**Price** **\$4.10**  
**Market cap** **\$39m**

#### Share price graph



#### Share details

Code CLBS  
 Listing NASDAQ  
 Shares in issue 9.55m

#### Business description

Caladrius Biosciences is developing cell therapy (CT) products targeting selected autoimmune and cardiology indications. Its lead candidate, CLBS03, an ex vivo expanded polyclonal T regulatory CT for the treatment of recent-onset type I diabetes (T1D), recently completed enrolment in a Phase II trial.

#### Bull

- Large market opportunity in T1D, with over 18,000 newly diagnosed patients in the US each year.
- CLBS03 granted fast-track and orphan drug designations from US FDA.
- Proprietary regulatory T-cell immunomodulatory platform could potentially be out-licensed or applied to other autoimmune indications.

#### Bear

- High development risk in targeted indications and high reliance on external suppliers/manufacturing.
- Additional funding or partnerships will be needed to advance CLBS03 through pivotal studies.
- Prior Phase II study of autologous CD34 infusion in post-ST-elevation myocardial infarction (STEMI) did not reach perfusion/imaging endpoint.

#### Analysts

Pooya Hemami, CFA +1 (646) 653 7026  
 Maxim Jacobs, CFA +1 (646) 653 7027  
[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

**EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.**

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2018]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.